XIENCE V Everolimus Eluting Coronary Stent System (EECSS) EXCEED: Evaluation of XIENCE V Catheterization Lab Endpoints and Excellence in Delivery.

Trial Profile

XIENCE V Everolimus Eluting Coronary Stent System (EECSS) EXCEED: Evaluation of XIENCE V Catheterization Lab Endpoints and Excellence in Delivery.

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Oct 2015

At a glance

  • Drugs Everolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms EXCEED
  • Sponsors Abbott Vascular
  • Most Recent Events

    • 21 Oct 2009 Actual end date (October 2009) added as reported by ClinicalTrials.gov
    • 21 Oct 2009 Status changed from active, no longer recruiting to completed as reportd by ClinicalTrials.gov
    • 18 Apr 2009 Actual patient number (2517) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top